Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C19H21NO6 |
| Molecular Weight | 359.3731 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCOC(=O)C1=C(C)NC(C)=C(C1C2=C3OCOC3=CC=C2)C(=O)OC
InChI
InChIKey=MSOAVHHAZCMHDI-UHFFFAOYSA-N
InChI=1S/C19H21NO6/c1-5-24-19(22)15-11(3)20-10(2)14(18(21)23-4)16(15)12-7-6-8-13-17(12)26-9-25-13/h6-8,16,20H,5,9H2,1-4H3
| Molecular Formula | C19H21NO6 |
| Molecular Weight | 359.3731 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Oxodipine is a dihydropyridine calcium channel blocker that has been developed by IQB as an antihypertensive agent. Experiments on dogs have shown that oxodipine exerted a relatively specific action on blood vessels without significant intrinsic negative chronotropic properties. in addition, in Europe, the drug was involved in phase III clinical trials in and in phase II for the treatment of Hypertension. Besides, oxodipine was studied for the treatment of ischaemic heart disorders. However, these studied were discontinued.
Originator
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:40:19 UTC 2023
by
admin
on
Fri Dec 15 15:40:19 UTC 2023
|
| Record UNII |
GPE63J28F0
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID50869063
Created by
admin on Fri Dec 15 15:40:19 UTC 2023 , Edited by admin on Fri Dec 15 15:40:19 UTC 2023
|
PRIMARY | |||
|
100000083051
Created by
admin on Fri Dec 15 15:40:19 UTC 2023 , Edited by admin on Fri Dec 15 15:40:19 UTC 2023
|
PRIMARY | |||
|
56108
Created by
admin on Fri Dec 15 15:40:19 UTC 2023 , Edited by admin on Fri Dec 15 15:40:19 UTC 2023
|
PRIMARY | |||
|
5650
Created by
admin on Fri Dec 15 15:40:19 UTC 2023 , Edited by admin on Fri Dec 15 15:40:19 UTC 2023
|
PRIMARY | |||
|
OXODIPINE
Created by
admin on Fri Dec 15 15:40:19 UTC 2023 , Edited by admin on Fri Dec 15 15:40:19 UTC 2023
|
PRIMARY | |||
|
C170275
Created by
admin on Fri Dec 15 15:40:19 UTC 2023 , Edited by admin on Fri Dec 15 15:40:19 UTC 2023
|
PRIMARY | |||
|
GPE63J28F0
Created by
admin on Fri Dec 15 15:40:19 UTC 2023 , Edited by admin on Fri Dec 15 15:40:19 UTC 2023
|
PRIMARY | |||
|
CHEMBL2105319
Created by
admin on Fri Dec 15 15:40:19 UTC 2023 , Edited by admin on Fri Dec 15 15:40:19 UTC 2023
|
PRIMARY | |||
|
90729-41-2
Created by
admin on Fri Dec 15 15:40:19 UTC 2023 , Edited by admin on Fri Dec 15 15:40:19 UTC 2023
|
PRIMARY | |||
|
SUB09545MIG
Created by
admin on Fri Dec 15 15:40:19 UTC 2023 , Edited by admin on Fri Dec 15 15:40:19 UTC 2023
|
PRIMARY | |||
|
C053783
Created by
admin on Fri Dec 15 15:40:19 UTC 2023 , Edited by admin on Fri Dec 15 15:40:19 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ENANTIOMER -> RACEMATE | |||
|
|
ENANTIOMER -> RACEMATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
